1. Home
  2. ZCMD vs IBIO Comparison

ZCMD vs IBIO Comparison

Compare ZCMD & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

N/A

Current Price

$1.84

Market Cap

6.1M

Sector

Real Estate

ML Signal

N/A

Logo iBio Inc.

IBIO

iBio Inc.

N/A

Current Price

$2.43

Market Cap

50.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZCMD
IBIO
Founded
2012
2008
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
50.4M
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
ZCMD
IBIO
Price
$1.84
$2.43
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.75
AVG Volume (30 Days)
181.5K
1.0M
Earning Date
01-01-0001
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
73.08
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.56
52 Week High
$1.93
$5.60

Technical Indicators

Market Signals
Indicator
ZCMD
IBIO
Relative Strength Index (RSI) 83.26 48.68
Support Level $1.02 $2.02
Resistance Level $1.93 $3.01
Average True Range (ATR) 0.14 0.26
MACD 0.14 -0.04
Stochastic Oscillator 98.57 16.05

Price Performance

Historical Comparison
ZCMD
IBIO

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Share on Social Networks: